ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV

The Defense Logistics Agency awarded a delivery order to TEVA PHARMACEUTICALS USA, INC. under the base contract SPE2DP20D0002 for 18 packs of Adenovirus Type 4 and Type 7 Vaccine, Live, with a total value of $343,526.40, issued on July 14, 2026, and requiring full delivery by July 21, 2026. The product is identified by NSN 6505016420106, NDC 51285-0138-50, CAGE code 0AZ22, and part number V24509A-20-07-CF-07, with the order placed under the procurement request 7017485354. Delivery is to be made to Fort Detrick, Maryland, as the primary site, with Fort Leonard Wood, Missouri, as an alternate location, and all shipments must utilize traceable freight methods excluding parcel post. Title and risk transfer to the government upon delivery, with the contractor bearing all transportation costs and responsibilities under FOB Destination terms. Payment will be processed by the Defense Finance and Accounting Service at Columbus, Ohio, under accounting code 97X4930 5CBX 001 2620 S33189, following DFARS 252.232-7003, which implies electronic invoicing via WAWF. The awardee, identified by CAGE 3V8D7, has certified as a Small Business, Small Disadvantaged Business, and Women-Owned Small Business, triggering applicable FAR and DFARS compliance and SAM reporting obligations. The contract does not specify packaging, preservation, or marking standards beyond requiring TCN W25MWY61940719 and CLIN/PR identifiers on all documentation, nor does it reference MIL-STDs or formal inspection criteria beyond requiring items to conform to contract specifications and be accepted by the government at destination. No formal evaluation factors, contract clauses, or special requirements are documented beyond the delivery order’s commercial and logistical terms, suggesting a streamlined, fixed-price procurement executed under an indefinite-delivery vehicle, with no options or modifications noted.